G1 Therapeutics Inc (NASDAQ:GTHX) Expected to Announce Earnings of -$0.97 Per Share

Wall Street brokerages expect G1 Therapeutics Inc (NASDAQ:GTHX) to announce earnings per share of ($0.97) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for G1 Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.90) and the lowest estimate coming in at ($1.07). G1 Therapeutics posted earnings of ($0.65) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 49.2%. The firm is scheduled to issue its next earnings report on Thursday, February 27th.

On average, analysts expect that G1 Therapeutics will report full-year earnings of ($3.29) per share for the current fiscal year, with EPS estimates ranging from ($3.39) to ($3.23). For the next financial year, analysts anticipate that the business will post earnings of ($4.36) per share, with EPS estimates ranging from ($5.34) to ($3.92). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow G1 Therapeutics.

G1 Therapeutics (NASDAQ:GTHX) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.86) EPS for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.01.

GTHX has been the subject of several research reports. BidaskClub cut shares of G1 Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 8th. HC Wainwright reissued a “buy” rating and issued a $72.00 price objective on shares of G1 Therapeutics in a research report on Thursday, December 12th. BTIG Research boosted their price objective on shares of G1 Therapeutics from $51.00 to $80.00 and gave the company a “buy” rating in a research report on Tuesday, January 7th. Zacks Investment Research cut shares of G1 Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 8th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $74.00 price objective on shares of G1 Therapeutics in a research report on Thursday, December 12th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $60.00.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. International Biotechnology Trust PLC boosted its holdings in G1 Therapeutics by 48.3% during the second quarter. International Biotechnology Trust PLC now owns 146,000 shares of the company’s stock worth $4,472,000 after buying an additional 47,518 shares in the last quarter. Marshall Wace North America L.P. boosted its stake in G1 Therapeutics by 147.6% during the second quarter. Marshall Wace North America L.P. now owns 16,393 shares of the company’s stock worth $503,000 after buying an additional 9,773 shares during the period. California State Teachers Retirement System boosted its stake in G1 Therapeutics by 1.3% during the third quarter. California State Teachers Retirement System now owns 52,765 shares of the company’s stock worth $1,202,000 after buying an additional 671 shares during the period. California Public Employees Retirement System boosted its stake in shares of G1 Therapeutics by 113.2% in the third quarter. California Public Employees Retirement System now owns 67,162 shares of the company’s stock valued at $1,530,000 after purchasing an additional 35,662 shares during the period. Finally, Redmile Group LLC boosted its stake in shares of G1 Therapeutics by 33.5% in the third quarter. Redmile Group LLC now owns 390,934 shares of the company’s stock valued at $8,905,000 after purchasing an additional 98,200 shares during the period. Hedge funds and other institutional investors own 77.25% of the company’s stock.

GTHX stock opened at $25.36 on Wednesday. G1 Therapeutics has a 12 month low of $13.87 and a 12 month high of $41.80. The company has a current ratio of 14.28, a quick ratio of 14.28 and a debt-to-equity ratio of 0.03. The company has a 50-day moving average price of $25.52 and a 200 day moving average price of $27.35. The stock has a market cap of $953.07 million, a PE ratio of -8.54 and a beta of 2.23.

About G1 Therapeutics

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial.

Featured Article: What is a Swap?

Get a free copy of the Zacks research report on G1 Therapeutics (GTHX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.